Regulatory conditions met for Novo Holdings' $16.5 billion acquisition of Catalent, sell factories to Novo Nordisk.

From Investing.com: 2024-12-14 12:15:55

Novo Holdings’ $16.5 billion acquisition of Catalent is set to be completed soon, with all regulatory closing conditions fulfilled. Novo Holdings will sell three Catalent factories to Novo Nordisk for $11 billion to boost production of weight-loss drug Wegovy. The deal will have a mid single-digit negative impact on Novo Nordisk’s operating profit growth in 2025. EU antitrust approval was granted in December. U.S. consumer groups and labor unions had raised concerns about the deal, but the FTC has not provided any updates since seeking more information in May.



Read more at Investing.com: Regulatory conditions on Novo Holdings’ $16.5 billion Catalent deal fulfilled, companies say By Reuters